ArticleThe American journal of pathology2002
Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.
Article in The American journal of pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 173 citations in OpenAlex.
- Genome-wide association study meta-analysis for quantitative ultrasound parameters of bone identifies five novel loci for broadband ultrasound attenuation.Human molecular genetics · 2017Pooled it
- The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patients.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2017Trial
- Evaluation of SOX4 levels in multiple myeloma patients.Haematologica · 2025Article
- Sequential therapy for extramedullary plasmacytoma of the palate: a rare case report with seven years of follow-up and literature review.Journal of cancer research and clinical oncology · 2024Review
- Progression of monoclonal gammopathy of undetermined significance to multiple myeloma is associated with enhanced translational quality control and overall loss of surface antigens.Journal of translational medicine · 2024Article
- Article
- Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation.BMC cancer · 2022Article
- The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring "Multiple Myelomas".Cancers · 2022Review
- Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma.Antibodies (Basel, Switzerland) · 2022Review
- Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing.Skeletal radiology · 2022Review
- Current Understanding of Myelomatous Mesenchymal Stromal Cells Extended through Advances in Experimental Methods.Cancers · 2020Review
- RET-independent signaling by GDNF ligands and GFRα receptors.Cell and tissue research · 2020Review
- Targeted Therapy With Immunoconjugates for Multiple Myeloma.Frontiers in immunology · 2020Review
- [Prognostic significance of CD56 and CD117 expression in patients with newly diagnosed multiple myeloma treated with bortezomib-based first-line therapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- Review
- Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.Targeted oncology · 2018Review
- Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.Clinics in laboratory medicine · 2017Review
- Flow cytometry-based immunophenotypic analysis of primary systemic light chain amyloidosis.Oncology letters · 2017Article
- Review
- What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.Current hematologic malignancy reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unlike monoclonal gammopathy of undetermined significance (MGUS) or non-Hodgkin's lymphomas (NHLs) with plasmacytoid differentiation, multiple myeloma (MM) is commonly associated with lytic bone lesions. Although the mechanisms of increased osteoclast activity are partially understood, comparatively little is known about the mechanisms that lead to the observed decrease in osteoblast function. Studies have shown neural cell adhesion molecule (NCAM) homophilic binding between MM cell lines and osteosarcoma cell lines, and that binding results in decreased osteoid production in vitro. Thus, we postulated that the expression of NCAM by MM cells contributes to lytic lesion formation by causing decreased osteoid production in vivo. We used immunohistochemistry in bone marrow core biopsies to assess NCAM expression in osteoblasts and plasma cells (PCs) in vitro. We found consistent, strong, uniform NCAM expression by the osteoblasts in all bone marrow core biopsies (352 of 352, 100%). Strong expression of NCAM by PCs correlated with the presence of lytic bone lesions (chi-square, 33.39: P <0.000; odds ratio, 16.9). There was also a strong correlation between NCAM expression and the diagnosis of MM in comparison to reactive PCs, MGUS, or NHLs with plasmacytoid differentiation (all P values <0.000). In conclusion, using immunohistochemistry, we found strong expression of NCAM by osteoblasts and that when equal to the intensity of osteoblast expression, NCAM expression by PCs correlates with the presence of lytic bone lesions and distinguishes MM from reactive plasmacytosis, NHLs with plasmacytoid differentiation, and most cases of MGUS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.